Positioning political selling, disclosed 2026-09-11
Options put/call open interest 0.23, read 2026-11-05
Ethical passes the values gate
Price440.31 USD
Fair value541.53
Ethical score76.6/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup425.76+3.4% to today ✓Distribution gives way to Markup
2026-10-02Read Distribution425.76+3.4% to today Accumulation gives way to Distribution after a 6% rise in 6 weeks
2026-08-19Read Accumulation400.82+9.9% to today ✓Distribution gives way to Accumulation
2026-08-13Read Distribution400.82+9.9% to today Accumulation gives way to Distribution after a 14% slide in 6 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Synopsys holds its Distribution at $440.31. The statistical read favours the sellers, held for 46 days.
As held on the ledger · 2026-11-05
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 46 days
Price at the screen
$440.31
Valuation
86.61 trailing · 26.38 forward price to earnings
Values screen
PASS· score 76.6
Beta
1.21
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.64%
Below 33%
Interest-bearing debt is just 29.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.15%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
9.20%
Below 49%
Money owed to the company is 9.2% of assets, under the 49% limit.
Pass
Revenue purity
3.94%
Below 5%
Only 3.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Synopsys clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and interest is about 4% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SNPS's ethical verdict changes
Today SNPS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 19% discount to our $541.53 fair value, narrow competitive moat, 42.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 18.7% discount to the base estimate.
Where our models see it going: fair-value estimate $541.53, with a range of $427.50 to $622.76, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
The quiet code behind every modern chip
Picture the phone in your pocket or the car on the road. None of it works without the complex chips inside, and Synopsys supplies the design software that lets engineers build those chips faster and with fewer errors. Revenue is rising 42 percent, the shares sit 33 percent below our fair value and the business clears our ethical screen without issue.
Forward earnings sit at 22 times, the narrow moat reflects solid but not unassailable technology, and margins remain modest at 9 percent with a 4 percent return on equity. Analysts see further upside to a 575 median target, yet the numbers show a steady compounder rather than a runaway winner.
Semiconductor cycles can still bite and competition from larger players keeps returns modest. The valuation already prices in much of the growth, so any slowdown would close the margin of safety quickly. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SNPS trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$467.61-0.1%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540.
2026-10-25Markup$468.11+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540.
2026-10-18Markup$468.11+9.9%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540.
2026-10-11Markup · changed$425.76+0.0%Entry 14
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 7.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540.
2026-08-26Accumulation$397.92+0.0%Entry 12
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Accumulation$397.92+0.0%Entry 11
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Accumulation$397.92+0.0%Entry 10
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Accumulation$397.92+0.0%Entry 9
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Accumulation$397.92+0.0%Entry 8
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (26 analysts) rates it buy, with a mean price target of $540. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
